Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure.

Vacková Š, Kikerlová S, Melenovsky V, Kolář F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Červenka L.

Kidney Blood Press Res. 2019 Aug 20:1-18. doi: 10.1159/000501688. [Epub ahead of print]

2.

Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart.

Widiapradja A, Manteufel EJ, Dehlin HM, Pena J, Goldspink PH, Sharma A, Kolb LL, Imig JD, Janicki JS, Lu B, Levick SP.

Sci Rep. 2019 Jul 29;9(1):11004. doi: 10.1038/s41598-019-47369-0.

3.

Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice.

Hye Khan MA, Stavniichuk A, Sattar MA, Falck JR, Imig JD.

Front Pharmacol. 2019 May 10;10:512. doi: 10.3389/fphar.2019.00512. eCollection 2019.

4.

A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.

Hye Khan MA, Schmidt J, Stavniichuk A, Imig JD, Merk D.

Biochem Pharmacol. 2019 Aug;166:212-221. doi: 10.1016/j.bcp.2019.05.023. Epub 2019 May 23.

PMID:
31129048
5.

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats.

Neckář J, Hye Khan MA, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A, Falck JR, Campbell WB, Sedláková L, Škutová Š, Olejníčková V, Gregorovičová M, Sedmera D, Kolář F, Imig JD.

Clin Sci (Lond). 2019 Apr 29;133(8):939-951. doi: 10.1042/CS20180728. Print 2019 Apr 30.

PMID:
30979784
6.

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.

Hrdlička J, Neckář J, Papoušek F, Husková Z, Kikerlová S, Vaňourková Z, Vernerová Z, Akat F, Vašinová J, Hammock BD, Hwang SH, Imig JD, Falck JR, Červenka L, Kolář F.

Front Pharmacol. 2019 Mar 1;10:159. doi: 10.3389/fphar.2019.00159. eCollection 2019.

7.

Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.

Wang E, Lu SX, Pastore A, Chen X, Imig J, Chun-Wei Lee S, Hockemeyer K, Ghebrechristos YE, Yoshimi A, Inoue D, Ki M, Cho H, Bitner L, Kloetgen A, Lin KT, Uehara T, Owa T, Tibes R, Krainer AR, Abdel-Wahab O, Aifantis I.

Cancer Cell. 2019 Mar 18;35(3):369-384.e7. doi: 10.1016/j.ccell.2019.01.010. Epub 2019 Feb 21.

PMID:
30799057
8.

Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.

Vacková Š, Kopkan L, Kikerlová S, Husková Z, Sadowski J, Kompanowska-Jezierska E, Hammock BD, Imig JD, Táborský M, Melenovský V, Červenka L.

Front Pharmacol. 2019 Jan 23;10:18. doi: 10.3389/fphar.2019.00018. eCollection 2019.

9.

MINA-1 and WAGO-4 are part of regulatory network coordinating germ cell death and RNAi in C. elegans.

Sendoel A, Subasic D, Ducoli L, Keller M, Michel E, Kohler I, Singh KD, Zheng X, Brümmer A, Imig J, Kishore S, Wu Y, Kanitz A, Kaech A, Mittal N, Matia-González AM, Gerber AP, Zavolan M, Aebersold R, Hall J, Allain FH, Hengartner MO.

Cell Death Differ. 2019 Feb 6. doi: 10.1038/s41418-019-0291-z. [Epub ahead of print]

PMID:
30728462
10.

Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction.

Imig JD.

Acta Physiol (Oxf). 2019 Jan;225(1):e13203. doi: 10.1111/apha.13203. Epub 2018 Oct 26. No abstract available.

PMID:
30307705
11.

Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats.

Miller BS, Blumenthal SR, Shalygin A, Wright KD, Staruschenko A, Imig JD, Sorokin A.

Diabetes. 2018 Nov;67(11):2206-2212. doi: 10.2337/db18-0308. Epub 2018 Aug 21.

12.

Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3.

Neckář J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprová M, Benák D, Hlaváčková M, Sotáková-Kašparová D, Falck JR, Sedmera D, Kolář F, Imig JD.

Am J Physiol Heart Circ Physiol. 2018 Nov 1;315(5):H1148-H1158. doi: 10.1152/ajpheart.00726.2017. Epub 2018 Aug 3.

PMID:
30074840
13.

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Sedláková L, Kikerlová S, Husková Z, Červenková L, Chábová VČ, Zicha J, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Krátký V, Červenka L, Kopkan L.

Biosci Rep. 2018 Sep 12;38(5). pii: BSR20171496. doi: 10.1042/BSR20171496. Print 2018 Oct 31.

14.

A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.

Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD.

Diabetologia. 2018 Oct;61(10):2235-2246. doi: 10.1007/s00125-018-4685-0. Epub 2018 Jul 21.

PMID:
30032428
15.

Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Imig JD.

Pharmacol Ther. 2018 Dec;192:1-19. doi: 10.1016/j.pharmthera.2018.06.015. Epub 2018 Jun 30. Review.

PMID:
29964123
16.

Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension.

Červenka L, Husková Z, Kopkan L, Kikerlová S, Sedláková L, Vaňourková Z, Alánová P, Kolář F, Hammock BD, Hwang SH, Imig JD, Falck JR, Sadowski J, Kompanowska-Jezierska E, Neckář J.

J Hypertens. 2018 Jun;36(6):1326-1341. doi: 10.1097/HJH.0000000000001708.

PMID:
29570510
17.

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.

Čertíková Chábová V, Kujal P, Škaroupková P, Varňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesař V, Červenka L.

Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6.

18.

Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

Kala P, Sedláková L, Škaroupková P, Kopkan L, Vaňourková Z, Táborský M, Nishiyama A, Hwang SH, Hammock BD, Sadowski J, Melenovský V, Imig JD, Červenka L.

Physiol Res. 2018 Jul 17;67(3):401-415. Epub 2018 Mar 12.

19.

Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis.

Yeboah MM, Hye Khan MA, Chesnik MA, Skibba M, Kolb LL, Imig JD.

Nephrol Dial Transplant. 2018 Aug 1;33(8):1333-1343. doi: 10.1093/ndt/gfx354.

20.

Orally Active Epoxyeicosatrienoic Acid Analogs.

Campbell WB, Imig JD, Schmitz JM, Falck JR.

J Cardiovasc Pharmacol. 2017 Oct;70(4):211-224. doi: 10.1097/FJC.0000000000000523. Review.

21.

Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia.

Bettaieb A, Koike S, Hsu MF, Ito Y, Chahed S, Bachaalany S, Gruzdev A, Calvo-Rubio M, Lee KSS, Inceoglu B, Imig JD, Villalba JM, Zeldin DC, Hammock BD, Haj FG.

Biochim Biophys Acta Gen Subj. 2017 Nov;1861(11 Pt A):2758-2765. doi: 10.1016/j.bbagen.2017.07.021. Epub 2017 Jul 27.

22.

Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition.

Skibba M, Hye Khan MA, Kolb LL, Yeboah MM, Falck JR, Amaradhi R, Imig JD.

Front Pharmacol. 2017 Jun 30;8:406. doi: 10.3389/fphar.2017.00406. eCollection 2017.

23.

Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans.

Gangadhariah MH, Dieckmann BW, Lantier L, Kang L, Wasserman DH, Chiusa M, Caskey CF, Dickerson J, Luo P, Gamboa JL, Capdevila JH, Imig JD, Yu C, Pozzi A, Luther JM.

Diabetologia. 2017 Jun;60(6):1066-1075. doi: 10.1007/s00125-017-4260-0. Epub 2017 Mar 28.

24.

Post-transcriptional control of executioner caspases by RNA-binding proteins.

Subasic D, Stoeger T, Eisenring S, Matia-González AM, Imig J, Zheng X, Xiong L, Gisler P, Eberhard R, Holtackers R, Gerber AP, Pelkmans L, Hengartner MO.

Genes Dev. 2016 Oct 1;30(19):2213-2225.

25.

Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Imig JD.

Adv Pharmacol. 2016;77:105-41. doi: 10.1016/bs.apha.2016.04.003. Epub 2016 May 5. Review.

26.

A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat.

Hye Khan MA, Hwang SH, Sharma A, Corbett JA, Hammock BD, Imig JD.

Prostaglandins Other Lipid Mediat. 2016 Sep;125:40-7. doi: 10.1016/j.prostaglandins.2016.07.003. Epub 2016 Jul 16.

27.

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Jíchová Š, Kopkan L, Husková Z, Doleželová Š, Neckář J, Kujal P, Vernerová Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Červenka L.

J Hypertens. 2016 Oct;34(10):2008-25. doi: 10.1097/HJH.0000000000001029.

28.

The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats.

Yeboah MM, Hye Khan MA, Chesnik MA, Sharma A, Paudyal MP, Falck JR, Imig JD.

Am J Physiol Renal Physiol. 2016 Sep 1;311(3):F576-85. doi: 10.1152/ajprenal.00288.2016. Epub 2016 Jun 29.

29.

p66Shc regulates renal vascular tone in hypertension-induced nephropathy.

Miller B, Palygin O, Rufanova VA, Chong A, Lazar J, Jacob HJ, Mattson D, Roman RJ, Williams JM, Cowley AW Jr, Geurts AM, Staruschenko A, Imig JD, Sorokin A.

J Clin Invest. 2016 Jul 1;126(7):2533-46. doi: 10.1172/JCI75079. Epub 2016 Jun 6.

30.

Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis.

Sharma A, Hye Khan MA, Levick SP, Lee KS, Hammock BD, Imig JD.

Int J Mol Sci. 2016 May 18;17(5). pii: E751. doi: 10.3390/ijms17050751.

31.

Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids.

Sporková A, Reddy RN, Falck JR, Imig JD, Kopkan L, Sadowski J, Červenka L.

Am J Med Sci. 2016 May;351(5):513-9. doi: 10.1016/j.amjms.2016.02.030. Epub 2016 Feb 23.

32.

Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites.

Imig JD, Hye Khan MA, Sharma A, Fish BL, Mandel NS, Cohen EP.

Am J Physiol Heart Circ Physiol. 2016 Jun 1;310(11):H1695-701. doi: 10.1152/ajpheart.00023.2016. Epub 2016 Apr 22.

33.

Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?

Imig JD.

Am J Physiol Renal Physiol. 2016 May 15;310(10):F1013-5. doi: 10.1152/ajprenal.00114.2016. Epub 2016 Mar 9. No abstract available.

34.

Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy.

Hye Khan MA, Fish B, Wahl G, Sharma A, Falck JR, Paudyal MP, Moulder JE, Imig JD, Cohen EP.

Clin Sci (Lond). 2016 Apr;130(8):587-99. doi: 10.1042/CS20150778. Epub 2016 Jan 15.

35.

Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Imig JD, Khan MA.

Compr Physiol. 2015 Dec 15;6(1):423-41. doi: 10.1002/cphy.c150009. Review.

36.

Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats.

Hye Khan MA, Sharma A, Rarick KR, Roman RJ, Harder DR, Imig JD.

PLoS One. 2015 Dec 18;10(12):e0145335. doi: 10.1371/journal.pone.0145335. eCollection 2015.

37.

Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.

Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA.

Purinergic Signal. 2015 Dec;11(4):519-31. doi: 10.1007/s11302-015-9470-7. Epub 2015 Sep 18.

38.

Reply to "Letter to the editor: 'Concern regarding quantification of urinary nephrin by commercially available ELISA'".

Sullivan JC, Imig JD.

Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F271. doi: 10.1152/ajprenal.00239.2015. No abstract available.

39.

Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats.

Alánová P, Husková Z, Kopkan L, Sporková A, Jíchová Š, Neckář J, Imig JD, Klevstig M, Kolář F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovský V, Červenková L, Kujal P, Vernerová Z, Červenka L.

Vascul Pharmacol. 2015 Oct;73:45-56. doi: 10.1016/j.vph.2015.08.013. Epub 2015 Aug 22.

PMID:
26304700
40.

Cooperative target mRNA destabilization and translation inhibition by miR-58 microRNA family in C. elegans.

Subasic D, Brümmer A, Wu Y, Pinto SM, Imig J, Keller M, Jovanovic M, Lightfoot HL, Nasso S, Goetze S, Brunner E, Hall J, Aebersold R, Zavolan M, Hengartner MO.

Genome Res. 2015 Nov;25(11):1680-91. doi: 10.1101/gr.183160.114. Epub 2015 Jul 31.

41.

HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages.

Vongrad V, Imig J, Mohammadi P, Kishore S, Jaskiewicz L, Hall J, Günthard HF, Beerenwinkel N, Metzner KJ.

PLoS One. 2015 Jul 30;10(7):e0132127. doi: 10.1371/journal.pone.0132127. eCollection 2015.

42.

Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.

Červenka L, Melenovský V, Husková Z, Sporková A, Bürgelová M, Škaroupková P, Hwang SH, Hammock BD, Imig JD, Sadowski J.

Physiol Res. 2015;64(6):857-73. Epub 2015 Jun 5.

43.

Tumour necrosis factor-α contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia.

Chytilová A, Borchert GH, Mandíková-Alánová P, Hlaváčková M, Kopkan L, Khan MA, Imig JD, Kolář F, Neckář J.

Acta Physiol (Oxf). 2015 May;214(1):97-108. doi: 10.1111/apha.12489. Epub 2015 Mar 28.

PMID:
25760892
44.

Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs.

Jahns H, Roos M, Imig J, Baumann F, Wang Y, Gilmour R, Hall J.

Nat Commun. 2015 Mar 6;6:6317. doi: 10.1038/ncomms7317.

45.

Epoxyeicosatrienoic acids, hypertension, and kidney injury.

Imig JD.

Hypertension. 2015 Mar;65(3):476-82. doi: 10.1161/HYPERTENSIONAHA.114.03585. Epub 2015 Jan 12. Review. No abstract available.

46.

miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction.

Imig J, Brunschweiger A, Brümmer A, Guennewig B, Mittal N, Kishore S, Tsikrika P, Gerber AP, Zavolan M, Hall J.

Nat Chem Biol. 2015 Feb;11(2):107-14. doi: 10.1038/nchembio.1713. Epub 2014 Dec 22.

PMID:
25531890
47.

Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ.

Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F131-9. doi: 10.1152/ajprenal.00531.2014. Epub 2014 Nov 5.

48.

WX-III-287-19 A Possible Thromboxane Antagonist in Bovine Coronary Arteries.

Shah AJ, Gauthier KM, Imig JD, Falck JR, Campbell WB.

Value Health. 2014 Nov;17(7):A732-3. doi: 10.1016/j.jval.2014.08.091. Epub 2014 Oct 26. No abstract available.

49.

Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury.

Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD.

Front Pharmacol. 2014 Sep 23;5:216. doi: 10.3389/fphar.2014.00216. eCollection 2014. Erratum in: Front Pharmacol. 2014;5:250.

50.

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.

Sporková A, Jíchová S, Husková Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L.

Clin Exp Pharmacol Physiol. 2014 Dec;41(12):1003-13. doi: 10.1111/1440-1681.12310.

Supplemental Content

Support Center